[Correspondence] Combination therapies in non-clear-cell renal cell carcinoma

January, 01, 2024 | Select Oncology Journal Articles

We read the Article by Laurence Albiges and colleagues1 with great interest. This study provides valuable insights into the treatment of non-clear-cell renal cell carcinoma with a combination of pembrolizumab and lenvatinib. However, the absence of a subgroup analysis focusing on cytoreductive nephrectomy substantially reduces the applicability of the findings, considering the potential effects of cytoreductive nephrectomy in this patient population.

For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –




Sign up for our emails

Trusted insights straight to your inbox and get the latest updates from OncWeekly

Privacy Policy